#ESMO22: Amgen drops the detailed deck for KRAS G12C, with eroding data likely to trigger fresh debate

PARIS — Amgen put its best foot forward in Paris early Monday, with the news that its KRAS G12C star Lumakras offered a solid benefit for patients suffering from advanced cases of non-small cell lung cancer compared with chemo. The top-line figures included a drop of 34% in the risk of...

Click to view original post